Financial Counselors Inc. reduced its holdings in Shire PLC (NASDAQ:SHPG) by 22.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,490 shares of the biopharmaceutical company’s stock after selling 2,156 shares during the quarter. Financial Counselors Inc.’s holdings in Shire were worth $1,147,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in SHPG. YorkBridge Wealth Partners LLC lifted its holdings in Shire by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 317 shares in the last quarter. BB&T Investment Services Inc. lifted its holdings in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 786 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Shire during the 2nd quarter worth $171,000. Stephens Inc. AR lifted its holdings in Shire by 22.2% during the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 228 shares in the last quarter. Finally, Ingalls & Snyder LLC lifted its holdings in Shire by 10.8% during the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 125 shares in the last quarter. 20.28% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have issued reports on SHPG. Barclays downgraded Shire from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI began coverage on Shire in a report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective on the stock. Royal Bank Of Canada reaffirmed a “buy” rating and set a $213.00 price objective on shares of Shire in a report on Monday, October 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 price objective on shares of Shire in a report on Sunday, October 8th. Finally, Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $212.18.
Shire (NASDAQ:SHPG) last issued its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion during the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.17 EPS. equities research analysts forecast that Shire PLC will post 15 earnings per share for the current fiscal year.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.